N-[2-(4-fluorophenyl)ethyl]piperazine bis(hydrochloride salt) | 349663-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(4-fluorophenyl)ethyl]piperazine bis(hydrochloride salt)
• 英文别名: 1-[2-(4-fluorophenyl)ethyl]piperazine, dihydrochloride；1-[2-(4-Fluorophenyl)ethyl]piperazine hydrochloride；1-[2-(4-fluorophenyl)ethyl]piperazine;hydrochloride
• CAS: 349663-44-1
• 化学式: C₁₂H₁₇FN₂*2ClH
• 分子量: 281.201
• InChiKey: XCJQNAMEFYFVQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[2-(4-fluorophenyl)ethyl]piperazine bis(hydrochloride salt) 、 三氟乙酸 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 生成 (4-chloro-1-methyl-1H-pyrazol-3-yl)-{4-[2-(4-fluoro-phenyl)-ethyl]-piperazin-1-yl}-methanone trifluoroacetate
  参考文献：
  名称：

  WO2008/42388

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氟溴乙基苯 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 15.0h， 生成 N-[2-(4-fluorophenyl)ethyl]piperazine bis(hydrochloride salt)
  参考文献：
  名称：

  Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators

  摘要：

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。

  公开号：

  EP2508526A1

文献信息

• [EN] SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE SPIROALCÈNECARBOXAMIDE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE CHEMOKINES
  申请人：ARES TRADING SA

  公开号：WO2012130915A1

  公开（公告）日：2012-10-04

  The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。
• Biologically Active Compounds through Catalysis: Efficient Synthesis ofN-(Heteroarylcarbonyl)-N′-(arylalkyl)piperazines
  作者：Kamal Kumar、Dirk Michalik、Ivette Garcia Castro、Annegret Tillack、Alexander Zapf、Michael Arlt、Timo Heinrich、Henning Böttcher、Matthias Beller

  DOI：10.1002/chem.200305327

  日期：2004.2.6

  practical route for the synthesis of new biologically active 5-HT(2 A) receptor antagonists has been developed. In only three catalytic steps, this class of central nervous system (CNS) active compounds can be synthesized efficiently with high diversity. As the initial step, an anti-Markovnikov addition of amines to styrenes provides an easy route to N-(arylalkyl)piperazines, which constitute the core structure

  已经开发了一种合成新的具有生物活性的5-HT（2 A）受体拮抗剂的实用途径。在仅三个催化步骤中，这类中枢神经系统（CNS）活性化合物可以高效，高度多样性地合成。作为第一步，胺向苯乙烯的反马尔科夫尼科夫加成法提供了一条通往N-（芳基烷基）哌嗪的简便方法，后者构成了活性分子的核心结构。在此，即使在室温下，苯乙烯与苄基哌嗪的碱催化的加氢胺化反应也以高收率进行。催化脱苄基作用后，游离胺已成功地用不同的芳族和杂芳族卤化物和一氧化碳进行羰基化，以良好或优异的收率得到所需化合物。两个关键的反应，
• Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof
  申请人：——

  公开号：US20040063723A1

  公开（公告）日：2004-04-01

  The present invention relates to a process for the preparation of(3-cyano-1H-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone and salts thereof, characterised in that an indole ester of the formula II in which R is as defined in Claim 1, is converter into 3-cyano-1H-indole-7-carboxylic acid via steps (1) to (4) according to Claim 1, and this is reacted with 1-[2-(4-fluorophenyl)ethyl]piperazine of salts thereof to give the product.

  本发明涉及一种制备(3-氰基-1H-吲哚-7-基)[4-(4-氟苯乙基)哌嗪-1-基]甲酮及其盐的方法，其特征在于，将式II中R如权利要求1所定义的吲哚酯通过步骤（1）至（4）转化为3-氰基-1H-吲哚-7-羧酸，然后与1-[2-(4-氟苯基)乙基]哌嗪或其盐反应，得到所述产物。
• PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Xiong Yifeng

  公开号：US20100004264A1

  公开（公告）日：2010-01-07

  Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT 2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  化合物公式（Ia）的吡唑衍生物及其药物组成物可调节5HT2A血清素受体的活性。化合物公式（Ia）及其药物组成物用于治疗失眠和相关睡眠障碍、血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、降低血栓形成的风险、哮喘或其症状、激动或其症状、行为障碍、药物引起的精神病、兴奋性精神病、Gilles de Ia Tourette综合征、躁狂障碍、有机或NOS精神病、精神病性障碍、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关障碍、糖尿病相关障碍、进行性多灶性白质脑病等。本发明还涉及联合单独或同时给予其他药物制剂的方法，用于治疗5-HT2A血清素受体介导的疾病。
• IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Xiong Yifeng

  公开号：US20110263592A1

  公开（公告）日：2011-10-27

  Imidazo[1,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  公式（Ia）的咪唑[1,2-α]吡啶衍生物及其制药组合物，可调节5-HT2A 5-羟色胺受体的活性。该化合物及其制药组合物适用于治疗失眠、睡眠障碍、血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、烦躁或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de Ia Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病性障碍、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物分别或联合使用治疗5-HT2A 5-羟色胺受体介导的疾病的方法。